RESPIRATORY ILLNESS AND RESPIRATORY SYNCYTIAL VIRUS (RSV)-RELATED HOSPITALIZATION (RSVH) IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES (CAA) IN THE CARESS REGISTRY (2005-2016)
Author(s)
Wong SK1, Paes B2, Li A1, Mitchell I3, Lanctôt KL1
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: Infants <2 years of age with congenital airway anomalies (CAA) may experience increased risks of respiratory illness-related (RIH) and RSV-related hospitalization (RSVH). This study compared RIH and RSVH hazards in infants with CAA versus infants prophylaxed for standard, approved indications (SD) and other serious underlying medical disorders (MD) in the Canadian RSV Evaluation Study of Palivizumab (CARESS). METHODS: CARESS is a prospective, observational study of children who received ≥1 injection of palivizumab across 32 Canadian hospital sites. Neonatal and demographic data were collected at enrolment. Post-injection data was collected monthly, including utilization and adherence, and outcomes related to respiratory illness events. RESULTS:
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PIN84
Topic
Study Approaches
Topic Subcategory
Registries
Disease
Infectious Disease (non-vaccine)
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now